Chen 2010.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 64. Age: aripiprazole group 18～50 years, mean = (22.35 ± 7.15) years; risperidone group 18～49 years, mean = (22.25 ± 9.55) years. Gender: aripiprazole group: 14 male, 18 female; risperidone group: 17 male, 15 female. History: aripiprazole group 1 month～10 years; risperidone group 1 month～9 years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐30 mg/day. Mean = (19.4 ± 2.1) mg/day. N = 32. 2. Risperidone: Dose range: 1‐6 mg/day. Mean = (2.7 ± 0.7)mg/day. N = 32.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐74%, improved: 25%‐49%, no effect: < 25%). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS general pathological subscale score. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Low riskUnclear riskHigh risk
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Low riskUnclear riskHigh risk
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	Data on TESS total score, nausea/vomiting, dizziness, blurred vision, insomnia, constipation, excitement, use of benzodiazepines and other medicines was missing.
Other bias	Low risk	None obvious.